Fig. 1: DDX3X overexpression correlates with a poor prognosis in PDAC patients.
From: DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression
A Gene expression analysis was conducted to compare DDX3X expression between normal pancreatic tissues and PAAD tissues from The Cancer Genome Atlas (TCGA) database, which was combined with the Genotype-Tissue Expression (GTEx) database. To further evaluate the expression of DDX3X between normal pancreas tissues and PDAC tissues, three GSE microarrays from GEO public databases (GSE60979, GSE91035 and GSE71989) were selected for verification. B DDX3X expression was assessed to determine its association with overall survival (OS) and disease-specific survival (DSS) in PAAD patients. The median mRNA value was used to categorize tumor samples into high and low-expression groups, and the P values were determined by a log-rank test (p = 0.029 and 0.014, respectively). C Immunohistochemical staining was performed to detect DDX3X in PDAC/adjacent normal pancreatic tissue samples, accompanied by hematoxylin-eosin (H&E) staining. D An analysis of DDX3X protein and mRNA levels was undertaken in human pancreatic ductal HPDE cells and cultured human PC cell lines to further support these findings. Data are shown as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. p values were calculated by Student’s t test.
